Weight-Loss Drug Makers Glean Strategic Insights from U.S. Litigation History
New York — As the United States grapples with rising obesity rates, manufacturers of the weight-loss drug class known as glucagon-like peptide-1 receptor agonists, or GLP-1, are drawing increased legal scrutiny. With this pharmaceutical success comes a lurking fear of mass tort litigation, a recurring theme in America’s complicated relationship with promising yet potentially risky medications. GLP-1 weight-loss drugs, lauded for their effectiveness in combating obesity, now face the challenge of navigating the perilous waters of American litigation. This scenario isn’t new. The history of pharmaceuticals in the U.S. is replete with legal battles over … Read more